The Dutch consortium aims to support early detection and treatment of Alzheimer’s disease

Photo:<. com

A public-private partnership has been established to support the diagnosis and personalized treatment of Alzheimer’s disease, consisting of 30 hospitals, insurance companies, charities and Philips, a high-tech medical device manufacturer.

As the consortium was dubbed, it will spend about 8.8 million euros on board over the next five years, of which 5 million euros will be donated by the Ministry of Health and Economy.

This project is part of a national dementia strategy launched last year. About 300,000 people in the Netherlands suffer from some form of dementia, and the aging population is expected to increase to 500,000 in 20 years.

Care for people with dementia puts pressure on public health and care services. “This is an urgent matter,” Wiesjevan der Flier, head of the Alzheimer’s Center at UMC Amsterdam, told Financieele Dagblad. “All the partners I approached were interested in joining. Such an extensive alliance is typical in a small country like the Netherlands.

Funder Flyer said the project is only the first step, but the large investment momentum needed is there and needs to be encouraged.

Early detection of Alzheimer’s disease (which can take decades to become apparent) is the biggest breakthrough in the fight against the disease, and the project builds on it, he said.

It also focuses on raising awareness of how lifestyle changes can delay or prevent illness, but more accurate predictions of how illness develops are individual. Helps to devise a cure for.

Another important goal, according to Funder Flyer, is to encourage public debate about Alzheimer’s disease, as it happened with cancer. “We are thirty years behind in that area,” she said.


Start-ups are also part of the consortium. Amsterdam-based company Neurocast analyzes typing behavior through a smartphone keyboard designed that may already show early signs of multiple sclerosis. The company wants to move from monitoring, diagnosing, and even predicting brain disease.

“As innovative players, we are very pleased to be in the company of such a well-known scientist and large corporation,” said Erwin Redeman, founder of Neurocast.

The company provides human resources and technology free of charge. “Instead, the model can be adapted to detect Alzheimer’s disease and put at the forefront of development.

Thank you for donating to

The team would like to thank all the generous readers for their donations over the last few weeks. Your financial support has helped extend the scope of the coronavirus crisis in the evenings and weekends and keep you up to date with the latest developments. Was free for 14 years, but without the financial support of our readers, we cannot provide fair and accurate news and features about everything in the Netherlands. Your contribution makes this possible.

If you haven’t donated yet but want to donate, You can do so through Ideal, credit card or Paypal.

The Dutch consortium aims to support early detection and treatment of Alzheimer’s disease

Source link The Dutch consortium aims to support early detection and treatment of Alzheimer’s disease

Back to top button